Nyxoah price target lowered to $14 from $15 at Stifel

Stifel analyst Jonathan Block lowered the firm’s price target on Nyxoah (NYXH) to $14 from $15 and keeps a Buy rating on the shares. The firm lowered its FY25-FY28 estimates but largely maintains its FY29 U.S. Genio market share estimate of about 16%, which assumes a U.S. duopoly with Inspire Medical (INSP). The firm expects Nyxoah’s label to be favorable to Inspire’s and prior diligence suggested 50%-plus of non-academic centers want to get trained on Genio within about six months of commercialization, which it calls “a greater uptake than Inspire’s high-level comments suggest.”